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Abstract
Background: It has been proposed that PPARα agonists stimulate Kupffer cells in rodents which
in turn, release mitogenic factors leading to hepatic hyperplasia, and eventually cancer. However,
Kupffer cells do not express PPARα receptors, and PPARα agonists stimulate hepatocellular
proliferation in both TNFα- and TNFα receptor-null mice, casting doubt on the involvement of
Kupffer cells in the mitogenic response to PPARα agonists. This study was therefore designed to
investigate whether the PPARα agonist PFOA and the Kupffer cell inhibitor methylpalmitate
produce opposing effects on hepatocellular proliferation and Kupffer cell activity in vivo, in a manner
that would implicate these cells in the mitogenic effects of PPARα agonists.
Methods:  Male Sprague-Dawley rats were treated intravenously via  the tail vein with
methylpalmitate 24 hrs prior to perfluorooctanoic acid (PFOA), and were sacrificed 24 hrs later,
one hr after an intraperitoneal injection of bromodeoxyuridine (BrdU). Sera were analyzed for
TNFα and IL-1β. Liver sections were stained immunohistochemically and quantified for BrdU
incorporated into DNA.
Results: Data show that PFOA remarkably stimulated hepatocellular proliferation in the absence
of significant changes in the serum levels of either TNFα or IL-1β. In addition, methylpalmitate did
not alter the levels of these mitogens in PFOA-treated animals, despite the fact that it significantly
blocked the hepatocellular proliferative effect of PFOA. Correlation between hepatocellular
proliferation and serum levels of TNFα or IL-1β was extremely poor.
Conclusion: It is unlikely that mechanisms involving Kupffer cells play an eminent role in the
hepatic hyperplasia, and consequently hepatocarcinogenicity attributed to PPARα agonists. This
conclusion is based on the above mentioned published data and the current findings showing
animals treated with PFOA alone or in combination with methylpalmitate to have similar levels of
serum TNFα and IL-1β, which are reliable indicators of Kupffer cell activity, despite a remarkable
difference in hepatocellular proliferation.
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Background
Treatment of rodents with agonists of PPARα results in
liver cancer via mechanisms that remain unclear. While
some studies implicate oxidative stress, caused by an over-
production of H2O2, as a consequence of peroxisome pro-
liferation [1], others have suggested that these agonists
increase rates of hepatocyte DNA synthesis leading even-
tually to the development of liver tumors [2,3].
In an attempt to delineate how PPARα agonists may initi-
ate hepatocellular proliferation, investigators have pro-
posed that these agonists stimulate Kupffer cells, the
resident liver macrophages, which in turn release
mitogenic factors leading to hepatic hyperplasia [2,4,5].
This conclusion is supported by the observation that pre-
sumed inactivation of Kupffer cells prevented the
mitogenic effect of the PPARα agonist Wy-14,643 [4]. Fur-
thermore, presence of nonparenchymal cells was required
for replicative DNA synthesis in hepatocytes cultured in
the presence of Wy-14,643 [6]. In addition, antibodies
against tumor necrosis factor alpha (TNFα), presumably
released by Kupffer cells upon their activation by agonists
of PPARα, blocked the increase in liver cell replication in
response to Wy-14,643. Finally, it was reported that TNFα
suppressed apoptosis and induced DNA synthesis, effects
which are similar to those produced by PPAR activators
[7].
Results of a previous study in our laboratory do not sup-
port the aforementioned conclusions [8], and others [9]
showed that activating the retinoid X receptors, the oblig-
atory heterodimer of PPAR, inhibited TNFα production
by isolated Kupffer cells. Importantly, it has been shown
that Kupffer cells do not express PPARα receptors [10],
and that PPARα agonists were able to stimulate hepatocel-
lular proliferation in both TNFα- and TNFα receptor-null
mice [11,12]. These findings cast doubt on the role of
Kupffer cells in the hepatocellular proliferation known to
occur in response to PPARα agonists in rodents.
Serum levels of TNFα and IL-1β are reliable indicators of
the Kupffer cell activity status [13]. Thus, according to the
hypothesis stipulating that PPARα agonists activate
Kupffer cells as a prerequisite for the induction of hepato-
cellular proliferation, PFOA is expected to elevate serum
levels of these mitogens. Also, it would be expected that
hepatocellular proliferation and serum levels of TNFα or
IL-1β will be blunted by methylpalmitate which is a
known inhibitor of Kupffer cells. Data show that PFOA at
a dose which remarkably stimulated hepatocellular prolif-
eration did not produce significant changes in the serum
levels of either TNFα or IL-1β. Furthermore, results reveal
that Kupffer cell activity and PFOA-induced hepatocellu-
lar proliferation are unrelated phenomena, as evidenced
by the fact that methylpalmitate did not diminish serum
levels of TNFα or IL-1β when given in combination with
PFOA, yet it significantly blocked the hepatocellular pro-
liferative effect of this PPARα agonist. It is therefore
unlikely that mechanisms involving the stimulation of
Kupffer cells are responsible for the hyperplasia and the
consequent hepatocarcinogenicity attributed to PPARα
agonists in rodents.
Methods
Animal treatment and determination of serum TNFα, IL-1β 
and triglycerides
Male Sprague-Dawley rats (150–200 g) were purchased
from Sasco (Omaha, NE). Animals received humane care
in compliance with the National Research Council's crite-
ria outlined in "Guide for the Care and Use of Laboratory
Animals." Rats were treated intravenously via the tail vein
with methylpalmitate (2 g/kg), or the 20% Tween 80+5%
glucose vehicle, 48 hrs prior to sacrifice. Rats also received
PFOA (100 mg/kg orally), or the corn oil vehicle, and
were sacrificed 24 hrs later, one hr after an intraperitoneal
injection of 100 mg/kg bromodeoxyuridine (BrdU) in
0.05 N NaOH. Animal sera were collected and analyzed
for TNFα, IL-1β using commercially available kits (R&R
Systems, Minneapolis, MN).
Measurement of hepatic peroxisomal β-oxidation activity 
and cell proliferation
β-Oxidation assays were performed on liver homogenates
as previously reported [14]. Briefly, liver samples were
excised and homogenized in 0.25 M sucrose (20% w/v).
Cyanide-insensitive palimtoyl-CoA oxidation was used as
a measure of activity of peroxisomal β-oxidation enzymes,
and was assayed by monitoring the rate of NAD+ reduc-
tion spectrophotometrically at 240 nm using the method
of Lazarow and DeDuve [15]. A unit of activity equals 1
µmol NAD+ reduced/min.
A mid-lobe radial section of the right anterior lobe of the
liver was flash frozen in liquid nitrogen, embedded in par-
affin and serial tissue sections were mounted onto poly-1-
lysine coated slides. Following deparaffination and dehy-
dration, one set of slides was stained immunohistochem-
ically for BrdU incorporation, routinely performed in our
laboratories [16,17]. Random areas of the slides were cho-
sen for counting stained and unstained hepatocytes
(>1000 cells/animal).
Statistical Analysis
Statistics were performed using one-way analysis of vari-
ance (ANOVA), or t-test, as appropriate P < .05 was con-
sidered significant.Journal of Carcinogenesis 2006, 5:26 http://www.carcinogenesis.com/content/5/1/26
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Results
Effect of methylpalmitate on PFOA-induced 
hepatocellular proliferation and peroxisomal β-oxidation
PFOA significantly increased liver/body weight ratios
from control values of 4.2 ± 0.2% to 5.5 ± 0.2%, an effect
which was not altered by prior administration of methyl-
palmitate (Fig 1A). Since the increase in liver weight in
response to PPAR agonists has a hyperplastic as well as a
hypertrophic component, we investigated the effect of
methylpalmitate on the hyperplastic component which is
blamed for the hepatocarcinogenic effect of these chemi-
cals. Methylpalmitate significantly reduced PFOA-
induced levels of BrdU incorporation into hepatocye DNA
(Fig 1B). Hepatocellular BrdU labeling index was 0.66 ±
0.21% in control rats (Fig 1B). PFOA increased labeling
indices to 5.8 ± 0.9% (Fig 1B), and pretreatment with
methylpalmitate diminished PFOA-induced labeling
indices by 57% (Fig 1B).
In contrast to the significant inhibitory effect exerted by
methylpalmitate on PFOA-induced hepatocellular prolif-
eration, methylpalmitate did not influence the ability of
this PPARα agonist to induce liver peroxisomal β-oxida-
tion activity. PFOA caused a significant increase in perox-
isomal β-oxidation activity from a basal value of 5.1 ±
0.53 mU/mg protein to19.1 ± 1.4 mU/mg protein (Fig
1C). Activity remained at 21.5 ± 1.8 mU/mg protein when
methylpalmitate was given simultaneously with PFOA
(Fig 1C).
Serum TNFα and IL-1β Levels in Treated Rats
In PFOA-treated animals, serum levels of TNFα were 67 ±
9 pg/ml (Fig 2). Treatment with methylpalmitate prior to
PFOA did not exert detectable effects on these levels reach-
ing 71 ± 5 pg/ml (Fig 2A). Similarly, serum levels of IL-1β
in PFOA-treated rats of 62 ± 8 pg/ml were not significantly
altered by prior administration of methylpalmitate, as lev-
els were 54 ± 6 pg/ml (Fig 2B). In examining whether
hepatocellular labeling indices correlated with serum lev-
els of either TNFα or IL-1β, it was found that such a corre-
lation did not exist, as r2 values ranged from 0.021 to
0.0016, respectively (Fig 3).
Discussion
Increased hepatocellular replication has been advanced as
an important factor in liver cancer induced by PPARα ago-
nists in rodents [18]. In an attempt to elucidate mecha-
nisms involved in the hepatocellular proliferation caused
by these agonists, studies have produced conflicting evi-
dence with regards to the role of Kupffer cells in this proc-
ess [19-23]. This study was therefore undertaken to test
the hypothesis that hyperplasia induced by PPARα ago-
nists correlates with Kupffer cell activity. The executed
experiments examined the effect of the selective PPARα
agonist, PFOA [24] on serum levels of TNFα and IL-1β,
reliable indicators of Kupffer cell activity [13], in the
absence and presence of methylpalmitate, known inhibi-
tor of Kupffer cell activity [8].
Consistent with previous studies [25], PFOA caused sig-
nificant hepatomegaly and hyperplasia in treated animals
(Fig 1A &1B). This effect was observed in the absence of a
Effect of methylpalmitate on liver/body weight ratios, hepato- cellular proliferation and peroxisomal β-oxidation in  response to the PPARα agonist PFOA Figure 1
Effect of methylpalmitate on liver/body weight ratios, 
hepatocellular proliferation and peroxisomal β-oxi-
dation in response to the PPARα agonist PFOA. Ani-
mals were treated, livers were excised, weighed, and liver/
body weight ratios were calculated (A). Hepatocyte BrdU 
labeling indices (B), and peroxisomal β-oxiation activity (C) 
were determined as described under "Methods". Data are 
means ± SEM of 5 animals per group. *p < 0.05 compared to 
the control group. **p < .01 compared to the PFOA group.
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concomitant effect on serum levels of TNFα and IL-1β (Fig
2). Furthermore, methylpalmitate which is a known
inhibitor of Kupffer cell activity failed to modulate the
effect of PFOA on TNFα and IL-1β serum levels (Fig 2),
while significantly diminishing its hepatoproliferative
effect (Fig 1B), dissociating these two phenomena.
Indeed, examining the relationship between BrdU hepa-
tocye labeling indices and serum TNFα and IL-1β levels in
all treated animals revealed a very poor correlation (Fig 3),
making the assertion that activation of Kupffer cells is a
prerequisite for the hepatocellular proliferation caused by
PPARα agonists a strenuous one.
It is noteworthy that results observed in this study with
methylpalmitate mimic very closely those we obtained
earlier with the mitochondrial inhibitor, rotenone [26]. In
a previous study, we showed that rotenone inhibited
hepatocellular proliferation in response to the PPARα
agonist Wy-14,643 without interfering with the ability of
this agonist to induce peroxisomal β-oxidation [26], an
effect observed in this study for methylpalmitate with
PFOA as the PPARα agonist (Fig 1B &1C). In addition,
preliminary results (not shown) indicate that methyl-
palmitate produces effects on serum lipid metabolites and
hepatocellular BrdU indices in the opposite direction
from those caused by the natural congener, palmitic acid.
This finding suggests that methylpalmitate may interfere
with intermediary metabolism in a manner that dimin-
ishes the cellular ability to produce energy necessary for
fueling cell proliferation. However, the exact mechanism
by which this fatty acid derivative selectively inhibits
hepatocyte, but not peroxisomal, proliferation in
Lack of correlation between BrdU labeling indices and serum  mitogen levels Figure 3
Lack of correlation between BrdU labeling indices 
and serum mitogen levels. Linear regression analyses 
were performed on data generated from animal groups 
depicted in Fig 1, for TNFα (A) and IL-1β (B).
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Effect of methylpalmitate on serum levels of TNFα and IL-1β Figure 2
Effect of methylpalmitate on serum levels of TNFα 
and IL-1β. Animals were treated, and sera were collected 
and analyzed for TNFα (A) and IL-1β (B) as described under 
"Methods". Data are means ± SEM of 5 animals per group.
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response to the PPARα agonists remains unclear, and
requires further investigation.
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